{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
phenyl aminosalicylate
to a specific field?
Status:
Investigational
Source:
NCT03429218: Phase 1 Interventional Completed Advanced Solid Tumors
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:crelosidenib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:carfloglitazar [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT03359785: Phase 2 Interventional Completed Schizophrenia
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03961529: Phase 3 Interventional Completed Atopic Dermatitis
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00880217: Phase 2 Interventional Completed Attention Deficit Hyperactivity Disorder
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Bavisant (also known as JNJ-31001074 or BEN-2001), a highly selective, active antagonist of the human H3 receptor that was invented by Johnson & Johnson for the treatment of attention-deficit hyperactivity disorder (ADHD). However, the result of clinical trials did not display significant clinical effectiveness in the treatment of adults with ADHD. BenevolentAI has started phase II clinical trials where investigated bavisant for ameliorating the excessive daytime sleepiness in patients with Parkinson’s disease, using one of the drug side effects is dose-dependent insomnia.
Class (Stereo):
CHEMICAL (ACHIRAL)
Idoxifene (also known as CB 7432), a novel selective estrogen receptor modulator, is originally discovered at the CRC Centre for Cancer Therapeutics, Institute. This drug participated in clinical trials phase II in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. In addition, in phase III in postmenopausal women after one year of idoxifene treatment. However, both studies were discontinued because of insufficient effectiveness.
Status:
Investigational
Source:
INN:clodoxopone [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Clodoxopone (LR 19731) is a hypoglycemic agent, developed in the 1980s by Italian company Lusofarmaco. In animal models, the drug lowered the plasma cholesterol and triglyceride levels in several experimental conditions after single or repeated treatments. Results of the clinical trials of the drug are not reported.
Status:
Investigational
Source:
NCT00244751: Phase 2 Interventional Completed Cirrhosis, Liver
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Farglitazar is a non-thiazolidinedione insulin sensitizer and agonist of peroxisome proliferator-activated receptor-gamma. GlaxoSmithKline was developing farglitazar for the treatment of liver fibrosis and Type 2 diabetes mellitus.
